Literature DB >> 27626295

Prediction of Drug Penetration in Tuberculosis Lesions.

Jansy P Sarathy1, Fabio Zuccotto2, Ho Hsinpin1, Lars Sandberg2, Laura E Via3, Gwendolyn A Marriner3, Thierry Masquelin4, Paul Wyatt2, Peter Ray2, Véronique Dartois1.   

Abstract

The penetration of antibiotics in necrotic tuberculosis lesions is heterogeneous and drug-specific, but the factors underlying such differential partitioning are unknown. We hypothesized that drug binding to macromolecules in necrotic foci (or caseum) prevents passive drug diffusion through avascular caseum, a critical site of infection. Using a caseum binding assay and MALDI mass spectrometry imaging of tuberculosis drugs, we showed that binding to caseum inversely correlates with passive diffusion into the necrotic core. We developed a high-throughput assay relying on rapid equilibrium dialysis and a caseum surrogate designed to mimic the composition of native caseum. A set of 279 compounds was profiled in this assay to generate a large data set and explore the physicochemical drivers of free diffusion into caseum. Principle component analysis and modeling of the data set delivered an in silico signature predictive of caseum binding, combining 69 molecular descriptors. Among the major positive drivers of binding were high lipophilicity and poor solubility. Determinants of molecular shape such as the number of rings, particularly aromatic rings, number of sp(2) carbon counts, and volume-to-surface ratio negatively correlated with the free fraction, indicating that low-molecular-weight nonflat compounds are more likely to exhibit low caseum binding properties and diffuse effectively through caseum. To provide simple guidance in the property-based design of new compounds, a rule of thumb was derived whereby the sum of the hydrophobicity (clogP) and aromatic ring count is proportional to caseum binding. These tools can be used to ensure desirable lesion partitioning and guide the selection of optimal regimens against tuberculosis.

Entities:  

Keywords:  Mycobacterium tuberculosis; caseum; drug penetration; granuloma; in vitro assay; principle component analysis

Mesh:

Substances:

Year:  2016        PMID: 27626295      PMCID: PMC5028112          DOI: 10.1021/acsinfecdis.6b00051

Source DB:  PubMed          Journal:  ACS Infect Dis        ISSN: 2373-8227            Impact factor:   5.084


  37 in total

1.  Impact of recovery on fraction unbound using equilibrium dialysis.

Authors:  Li Di; John P Umland; Patrick E Trapa; Tristan S Maurer
Journal:  J Pharm Sci       Date:  2011-12-09       Impact factor: 3.534

2.  Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions.

Authors:  Maria C Kjellsson; Laura E Via; Anne Goh; Danielle Weiner; Kang Min Low; Steven Kern; Goonaseelan Pillai; Clifton E Barry; Véronique Dartois
Journal:  Antimicrob Agents Chemother       Date:  2011-10-10       Impact factor: 5.191

3.  Effect of subinhibitory concentrations of ciprofloxacin on Mycobacterium fortuitum mutation rates.

Authors:  Stephen H Gillespie; Shreya Basu; Anne L Dickens; Denise M O'Sullivan; Timothy D McHugh
Journal:  J Antimicrob Chemother       Date:  2005-06-14       Impact factor: 5.790

4.  In vitro protein binding characteristics of isoniazid, rifampicin, and pyrazinamide to whole plasma, albumin, and alpha-1-acid glycoprotein.

Authors:  J Woo; W Cheung; R Chan; H S Chan; A Cheng; K Chan
Journal:  Clin Biochem       Date:  1996-04       Impact factor: 3.281

5.  Metronidazole prevents reactivation of latent Mycobacterium tuberculosis infection in macaques.

Authors:  Philana Ling Lin; Veronique Dartois; Paul J Johnston; Christopher Janssen; Laura Via; Michael B Goodwin; Edwin Klein; Clifton E Barry; Joanne L Flynn
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-23       Impact factor: 11.205

Review 6.  The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells.

Authors:  Véronique Dartois
Journal:  Nat Rev Microbiol       Date:  2014-02-03       Impact factor: 60.633

7.  Selective Inactivity of Pyrazinamide against Tuberculosis in C3HeB/FeJ Mice Is Best Explained by Neutral pH of Caseum.

Authors:  Jean-Philippe Lanoix; Thomas Ioerger; Aimee Ormond; Firat Kaya; James Sacchettini; Véronique Dartois; Eric Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2015-11-16       Impact factor: 5.191

8.  Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910.

Authors:  Anne J Lenaerts; Donald Hoff; Sahar Aly; Stefan Ehlers; Koen Andries; Luis Cantarero; Ian M Orme; Randall J Basaraba
Journal:  Antimicrob Agents Chemother       Date:  2007-05-21       Impact factor: 5.191

9.  Location of intra- and extracellular M. tuberculosis populations in lungs of mice and guinea pigs during disease progression and after drug treatment.

Authors:  Donald R Hoff; Gavin J Ryan; Emily R Driver; Cornelius C Ssemakulu; Mary A De Groote; Randall J Basaraba; Anne J Lenaerts
Journal:  PLoS One       Date:  2011-03-21       Impact factor: 3.240

10.  Bedaquiline and Pyrazinamide Treatment Responses Are Affected by Pulmonary Lesion Heterogeneity in Mycobacterium tuberculosis Infected C3HeB/FeJ Mice.

Authors:  Scott M Irwin; Brendan Prideaux; Edward R Lyon; Matthew D Zimmerman; Elizabeth J Brooks; Christopher A Schrupp; Chao Chen; Matthew J Reichlen; Bryce C Asay; Martin I Voskuil; Eric L Nuermberger; Koen Andries; Michael A Lyons; Véronique Dartois; Anne J Lenaerts
Journal:  ACS Infect Dis       Date:  2016-02-24       Impact factor: 5.084

View more
  46 in total

1.  In Vitro Study of Stepwise Acquisition of rv0678 and atpE Mutations Conferring Bedaquiline Resistance.

Authors:  Shaheed V Omar; Remco P H Peters; Nabila Ismail; Nazir A Ismail
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

2.  Modeling and Simulation of Pretomanid Pharmacokinetics in Pulmonary Tuberculosis Patients.

Authors:  Michael A Lyons
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

Review 3.  Dynamic balance of pro- and anti-inflammatory signals controls disease and limits pathology.

Authors:  Joseph M Cicchese; Stephanie Evans; Caitlin Hult; Louis R Joslyn; Timothy Wessler; Jess A Millar; Simeone Marino; Nicholas A Cilfone; Joshua T Mattila; Jennifer J Linderman; Denise E Kirschner
Journal:  Immunol Rev       Date:  2018-09       Impact factor: 12.988

4.  Mycobacterium tuberculosis Is Selectively Killed by Rifampin and Rifapentine in Hypoxia at Neutral pH.

Authors:  Angelo Iacobino; Giovanni Piccaro; Federico Giannoni; Alessandro Mustazzolu; Lanfranco Fattorini
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

5.  An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions.

Authors:  Jansy P Sarathy; Hsin-Pin Ho Liang; Danielle Weiner; Jacqueline Gonzales; Laura E Via; Véronique Dartois
Journal:  J Vis Exp       Date:  2017-05-08       Impact factor: 1.355

Review 6.  The present state of the tuberculosis drug development pipeline.

Authors:  M Daben J Libardo; Helena Im Boshoff; Clifton E Barry
Journal:  Curr Opin Pharmacol       Date:  2018-08-23       Impact factor: 5.547

7.  The Funnel: a Screening Technique for Identifying Optimal Two-Drug Combination Chemotherapy Regimens.

Authors:  G L Drusano; Sarah Kim; Mohammed Almoslem; Stephan Schmidt; D Z D'Argenio; Jenny Myrick; Brandon Duncanson; Jocelyn Nole; David Brown; C A Peloquin; Michael Neely; Walter Yamada; Arnold Louie
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

Review 8.  Cavitary tuberculosis: the gateway of disease transmission.

Authors:  Michael E Urbanowski; Alvaro A Ordonez; Camilo A Ruiz-Bedoya; Sanjay K Jain; William R Bishai
Journal:  Lancet Infect Dis       Date:  2020-05-05       Impact factor: 25.071

9.  Pharmacokinetics of rifapentine and rifampin in a rabbit model of tuberculosis and correlation with clinical trial data.

Authors:  Dalin Rifat; Brendan Prideaux; Radojka M Savic; Michael E Urbanowski; Teresa L Parsons; Brian Luna; Mark A Marzinke; Alvaro A Ordonez; Vincent P DeMarco; Sanjay K Jain; Veronique Dartois; William R Bishai; Kelly E Dooley
Journal:  Sci Transl Med       Date:  2018-04-04       Impact factor: 17.956

Review 10.  NTM drug discovery: status, gaps and the way forward.

Authors:  Mu-Lu Wu; Dinah B Aziz; Véronique Dartois; Thomas Dick
Journal:  Drug Discov Today       Date:  2018-04-07       Impact factor: 7.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.